On May 10, 2018 Amgen (NASDAQ:AMGN) reported that it will present at the Bank of America Merrill Lynch 2018 Health Care Conference at 10 a.m. PT on Tuesday, May 15, 2018 (Press release, Amgen, MAY 10, 2018, View Source;p=RssLanding&cat=news&id=2348608 [SID1234526464]). David W. Meline, executive vice president and chief financial officer at Amgen, and David M. Reese, senior vice president of Translational Sciences and Oncology at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for at least 90 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 10, 2018 Alkermes plc (NASDAQ: ALKS) reported that its corporate presentation will be webcast live at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:20 a.m. PT (2:20 p.m. ET/7:20 p.m. BST) from Las Vegas (Press release, Alkermes, MAY 10, 2018, View Source;p=RssLanding&cat=news&id=2348542 [SID1234526463]). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Contact:
Jennifer Zibuda
Corporate Communications
+1 781 609 6129

On May 10, 2018 Aduro Biotech, Inc. (NASDAQ:ADRO) reported that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV on Thursday, May 17, 2018, at 9:35 am Pacific Time (Press release, Aduro Biotech, MAY 10, 2018, View Source;p=RssLanding&cat=news&id=2348537 [SID1234526462]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast and subsequent archived recording of this and other company presentations, please visit Aduro’s website at www.aduro.com

On May 10, 2018 Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, reported that management will attend the following conferences (Press release, Aclaris Therapeutics, MAY 10, 2018, View Source [SID1234526461]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will host investor meetings during the Bank of America Merrill Lynch’s 2018 Healthcare Conference in Las Vegas, NV on Wednesday, May 16, 2018.

Dr. Neal Walker, President and Chief Executive Officer, will present at the Jefferies 2018 Healthcare Conference in New York, NY on Tuesday, June 5, 2018 at 1:30 PM EST. Management will also host investor meetings on Tuesday, June 5, 2018.

Dr. Neal Walker, President and Chief Executive Officer, will present at the William Blair 38th Annual Growth Stock Conference in Chicago, IL on Wednesday, June 13, 2018at 11:20 AM CT. Management will also host investor meetings on Wednesday, June 13, 2018.

Management will participate on panels and host investor meetings during the 2018 Cantor Dermatology & Aesthetics Summit in New York, NY on Tuesday, June 19, 2018.

Management will participate on a panel and host investor meetings during the 2018 JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 20, 2018.
A live webcast of the Jefferies 2018 Healthcare Conference presentation and the William Blair 38th Annual Growth Stock Conference presentation may be accessed through the Company’s web site, www.aclaristx.com, on the ‘Events and Presentations’ section. An archived version of the presentation will be available for 30 days.

On May 10, 2018 FORMA Therapeutics (FORMA), a fully-integrated research and development biotechnology company, reported an abstract featuring the company’s selective, small molecule IDH1m inhibitor, FT-2102, has been selected for an oral presentation at the upcoming 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which will be held from June 1-5, 2018 in Chicago, Illinois (Press release, Forma Therapeutics, MAY 10, 2018, View Source [SID1234526429]). Details on the presentation are included below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date and Time: Monday, June 4, 2018, 4:30 PM – 6:00 PM

Session Title: Targeted Therapy in Leukemia

Session Type: Oral Abstract Session Title: A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Abstract No.: 7009